Eculizumab Safety: Five-Year Experience From the Global Atypical Hemolytic Uremic Syndrome Registry

Eculizumab Safety: Five-Year Experience From the Global Atypical Hemolytic Uremic Syndrome Registry

Introduction: Eculizumab has transformed outcomes for patients with atypical hemolytic uremic syndrome (aHUS). Its efficacy and safety profile was well characterized in the clinical trial program. The long-term safety profile was not previously assessed or compared against nontreated patients in an...

Full description

Bibliographic Details
Main Authors: Eric Rondeau, Spero R. Cataland, Imad Al-Dakkak, Benjamin Miller, Nicholas J.A. Webb, Daniel Landau, MD
Format: Article
Language:English
Published: Elsevier 2019-11-01
Series:Kidney International Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S2468024919314378

Similar Items

Similar Items